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Abstract
Total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) are heritable risk factors for cardiovascular disease,
yet the molecular mechanisms underlying the majority of blood lipid-associated genome-wide association studies signals
remain elusive. One association signal is located in intron 3 of VLDLR; rs3780181-A is a risk allele associated (P ≤ 2 × 10−9)
with increased TC and LDL-C. We investigated variants, genes and mechanisms underlying this association signal. We used
a functional genetic approach to show that the intronic region spanning rs3780181 exhibited 1.6–7.6-fold enhancer activity
in human HepG2 hepatocyte, THP-1 monocyte and Simpson-Golabi-Behmel Syndrome (SGBS) preadipocyte cells and that
the rs3780181-A risk allele showed significantly less enhancer activity compared with the G allele, consistent with the
direction of an expression quantitative trait locus in liver. In addition, rs3780181 alleles showed differential binding to
multiple nuclear proteins, including stronger IRF2 binding to the rs3780181 G allele. We used a CRISPR-cas9 approach to
delete 475 and 663 bp of the putative enhancer element in HEK293T kidney cells; compared to expression of mock-edited
cell lines, the homozygous enhancer deletion cell lines showed 1.2-fold significantly (P < 0.04) decreased expression of
VLDLR, as well as 1.5-fold decreased expression of SMARCA2, located 388 kb away. Together, these results identify an
enhancer of VLDLR expression and suggest that altered binding of one or more factors bound to rs3780181 alleles decreases
enhancer activity and reduces at least VLDLR expression, leading to increased TC and LDL-C.
Introduction
Low-density lipoprotein cholesterol (LDL-C) and total choles-
terol (TC) are heritable risk factors for cardiovascular dis-
ease (1,2), and genome-wide association studies (GWASs)
for lipid traits have identified association signals at least
240 loci (3,4). At one locus identified in Europeans, non-
coding variant rs3780181 A allele (Minor allele frequency,
MAF = 0.05), located in VLDLR intron 3, is significantly
associated with increased LDL-C (P = 2.0 × 10−9; n = 172 000;
Supplementary Material, Fig. S1) and TC (P = 7.0 × 10−10,
n = 186 000) (5). rs3780181 showed the same direction of
association with LDL-C in East Asians (MAF = 0.08) and a
meta-analysis of European and East Asian data increased the
evidence for association (P = 5.1 × 10−10, n = 203 746) (6). In
a Chinese population association study, rs3780181 shared the
same direction of effect, and was also associated (P < 0.05) with
increased TC and LDL-C (7). Among GWAS data for 68 lipoprotein
subclasses, rs3780181 showed the strongest association with
concentration of chylomicrons and largest VLDL particles
(P = 0.05) and LDL diameter (P = 0.09) (8). This association signal
is independent (r2 < 0.05) from other variants within 1 Mb of the
VLDLR gene that have been associated with circulating plasma
levels of vascular endothelial growth factor (VEGF), interleukin
levels and systolic blood pressure (9,10).
Association studies do not identify the underlying molec-
ular mechanisms, including the causal genes and variants,
that can be used to understand biological processes and
detect or validate therapeutic targets. For the majority of
associated variants located in non-coding intergenic and
intronic regions, risk variants may affect one or more genes
located up to hundreds of kilobases (kb) away (11–13). Two
strategies to link non-coding GWAS association signals to
candidate genes are identification of a colocalized associa-
tion of the same variants with expression level of a gene
(expression quantitative trait locus, eQTL) and observation
of more physical interaction/contact between the regulatory
variants and the promoter of a target gene than expected by
chance (14,15). These association-based methods are valuable
to suggest plausible candidate genes but do not show that the
associated variants have a causal effect on expression.
A more rigorous conclusion about the target gene(s) of a
GWAS signal requires identifying a mechanistic link between a
causal variant and an increased or decreased gene expression
or function. Evidence for a causal role of a non-coding variant
includes allelic differences in transcription factor binding and
regulatory activity of gene expression (16,17). Causal connections
between a regulatory variant and gene expression detected in
extrachromosomal assays can be validated by assaying regula-
tory effects in the context of the genome, such as through the
use of genome editing (18,19).
In this study, we conducted a systematic analysis of the vari-
ants and genes at the LDL-C and TC signal at the VLDLR GWAS
locus. We identify allelic differences in transcription factor
binding and transcriptional activity in three cell types and show
that these differences are consistent with associations observed
in human liver. We demonstrate that deletion of the intronic
enhancer containing the risk allele affects VLDLR expression.
Together these data provide a molecular mechanism for this
GWAS locus.
Results
Characteristics of candidate genes
To identify candidate genes at the rs3780181 signal, we examined
gene expression patterns, eQTL and physical interactions in
available data sets. The region within 500 kb of rs3780181
includes four protein-coding genes (SMARCA2, VLDLR, KCNV2
and KIAA0020-PUM3; Supplementary Material, Fig. S1). VLDLR
and SMARCA2 are expressed across multiple tissues including
liver and adipose, while KCNV2 is primarily expressed in testes
(Supplementary Material, Fig. S2). While rs3780181 did not show
association with expression level of any gene in Genotype-
Tissue Expression (GTEx) v6 (P < 0.05), rs3780181 was the lead
variant associated with VLDLR expression level in two human
liver eQTL data sets of 966 (P = 1.4 × 10−7) and 225 (P = 2.0 × 10−7)
individuals (20,21). In both data sets, the rs3780181-A risk
allele was associated with less VLDLR expression. The study
by Giambartolomei et al. (20) further demonstrated that the
GWAS and eQTL signals were colocalized using COLOC (posterior
probability of colocalization, 91%). Neither of the liver eQTL data
sets showed suggestive evidence of association with other genes
within 500 kb. Chromatin interaction data from mesenchymal
stem cells, human embryonic stem cells and human liver tissue
showed the most significant interactions (P < 2.6 × 10−13)
between the region containing rs3780181 and the promoter
regions of VLDLR and KCNV2 (Supplementary Material, Fig. S3).
These data suggest that expression of VLDLR and/or KCNV2 may
be affected by the GWAS variant(s).
Characterization and functional annotation of GWAS
variants
To identify the candidate variants at the GWAS signal, we evalu-
ated variant linkage disequilibrium (LD) with rs3780181, which
is the lead GWAS variant for TC and LDL-C and is located in
intron 3 of VLDLR (Supplementary Material, Fig. S4). rs3780181
is a common variant (minor allele frequency = 0.05) and not
in high LD (r2 ≥ 0.7) with any other variants in Europeans
(Supplementary Material, Fig. S1), suggesting that rs3780181 is
the strongest candidate functional variant for the GWAS signal.
To identify appropriate cell types to consider for regulatory
activity, we evaluated epigenomic evidence of potential regula-
tory activity across the full set of available cell and tissue types.
Based on Encyclopedia of DNA Elements (ENCODE), Roadmap
and Regulome database (RegulomeDB) data sets, rs3780181 is
located in a predicted enhancer region in HepG2 liver carci-
noma cells, human liver, ovary and fetal adrenal gland tissues
(Supplementary Material, Fig. S4) (22). rs3780181 also overlaps
a region of accessible chromatin in HepG2 and Huh7 cells, and
the genomic sequence around the variant shows sequence sim-
ilarity to a consensus DNA-binding motif for HMG, RXRA, Pax4,
Pax5, NKX3.2, STAT, BCL, Isgf3g, PRDM1 and multiple IRF proteins
including IRF1, IRF2 and IRF7 (Supplementary Material, Fig. S5).
rs37801810 exhibits allelic differences in enhancer
activity
Based on the eQTL for VLDLR in human liver (20,21), its
role in adipocyte–macrophage interactions and inflamma-
tion (23) and variant annotations, we evaluated the allelic
effects of rs3780181 using transcriptional reporter assays in
HepG2 hepatocytes, THP-1 monocytes and Simpson-Golabi-
Behmel Syndrome (SGBS) preadipocyte cells (Fig. 1A–C). A
223 bp element containing the G allele showed enhancer
activity as high as 4.1-fold in HepG2, 7.6-fold in THP-1 and
1.7-fold in SGBS. In all three cell types and in both orientations
with respect to a minimal promoter, elements containing the
risk A allele displayed less transcriptional activity than elements
containing the risk G allele. The alleles showed the largest
magnitude of differences in THP-1 cells (Fig. 1A). In the forward
orientation, the risk A allele had 2.1-fold higher enhancer
activity and the G allele had 5.1-fold higher enhancer activity
than the empty vector (P = 0.02), and in the reverse orientation,
the risk A allele had 4.6-fold higher and the G allele had 6.6-
fold higher activity than the empty vector (P = 0.1). These data
demonstrate that rs3780181 is present in an enhancer element
and that the non-risk G allele has significantly higher enhancer
activity than the risk A allele, consistent with the direction of
the rs3780181 association with VLDLR expression level in the
liver eQTL studies.
IRF2 and other proteins are differentially bound to
rs3780181 alleles
To test whether rs3780181 affects transcription factor binding,
we performed electrophoretic mobility shift assays (EMSAs)
using THP-1 and HepG2 nuclear protein extract. With THP-
Figure 1. GWAS lead variant rs3780181 displays allelic differences in transcriptional activity and protein binding. A 222 bp element containing the A allele showed
less enhancer activity when compared to the G allele in (A) THP-1, (B) HepG2 and (C) SGBS cells. We tested 3–5 clones per allele in both orientations with respect to
the minimal promoter and normalized activity to the EV. (D) EMSA with THP-1 NE and oligonucleotide probes centered on rs3780181 revealed at least two protein
complexes specific to the G allele (black arrows, lane 6) and two specific to the A allele (white arrows, lane 1). Protein complexes non-specifically bound to both allele
probes are denoted by gray arrows. The addition of anti-IRF2 antibody (lanes 5 and 10) caused a supershift of the larger G allele-specific band (lane 10). (E) The motif for
IRF-2 shows homology to the DNA region around rs3780181. The variant location is indicated by a rectangle and the variant alleles are shown in the probe sequences
below.
1 extract, we resolved four protein–probe complexes (Fig. 1D,
black and white arrows) that were differentially bound to the
alleles (lanes 1 and 6). The two proteins differentially bound
to the G allele were reduced more by including excess (35×)
unlabeled competitor G-allele probe than competitor A-allele
probe, providing further evidence of allele specificity. Similarly,
one protein differentially bound to the A allele was reduced
more by including excess unlabeled competitor A-allele probe.
EMSAs with HepG2 nuclear extract (NE) similarly showed two
protein complexes differentially bound to each allele, although
differences exist, especially for proteins bound to both alleles
(Supplementary Material, Fig. S6). To identify the factors bound
to the rs3780181 alleles, we conducted a DNA affinity pull-down
assay by using rs3780181 probes and THP-1 nuclear extract.
Among the transcription factors identified by the pull-down
assay (Supplementary Material, Table S1), the IRF2 consensus-
binding site motif matched the genomic sequence surrounding
rs3780181 best, and while the motif includes a C allele most
often at the site of the variant, G is observed more frequently
than A in the motif (Fig. 1E). Supershift assays with antibodies to
IRF2 and nuclear extracts from THP-1 and HepG2 confirmed that
IRF2 was specifically bound to the G allele (Fig. 1D, lane 10, and
Supplementary Material, Fig. S6, lane 10). Antibodies to five other
transcription factors suggested by ENCODE and TRANScription
FACtor database (TRANSFAC) motifs (see Materials and Methods
section) did not result in a supershift. These data show that the
risk A allele binds more strongly than the G allele to at least
one protein and disrupts the binding of IRF2 and one other G
allele-specific protein, suggesting that one or more of these
transcription factors mediates the effect of rs3780181 alleles on
transcriptional activity.
Enhancer deletion reduces VLDLR and SMARCA2
expression
To directly test the role of the enhancer containing rs3780181 on
expression of the candidate genes, we genetically engineered
two deletions of the enhancer element in human HEK293T
cells. We isolated 6 clonal cell lines homozygous for deletion of
475 bp (Enh1) and 6 lines homozygous for a deletion of 663 bp
(Enh2). Both deletions span rs3780181 and the 223 bp element
that showed allelic differences in enhancer activity (Fig. 2 and
Supplementary Material, Fig. S7). For controls, we used mock-
edited (control) clonal cell lines and wild-type (WT) HEK293T
cells with an intact enhancer containing rs3780181. We quan-
tified the expression of all genes located within 500 kb, VLDLR,
SMARCA2 and KCNV2, and normalized to the housekeeping gene
ACTB. Compared to the control cell lines, the Enh2 cell lines
showed 50% reduced expression (P < 0.05) of both VLDLR and
SMARCA2 (Fig. 2B and C) and the Enh1 cell lines showed 14
and 27% reduced expression for the same genes, respectively.
KCNV2 showed only nominal expression in all the tested
cell lines. A control gene located on a different chromosome,
VEGFA, did not have significantly reduced expression (P > 0.05)
in the engineered cell lines (Supplementary Material, Fig. S8).
These data show that deletion of the DNA element containing
rs3780181 can decrease expression of VLDLR and SMARCA2
consistent with its putative role as an enhancer.
Figure 2. Deletion of an enhancer containing rs3780181 leads to decreased VLDLR and SMARCA2 gene expression. (A) The DNA region (chr9:1 977 106–2 919 542; hg19)
from rs3780181 with the three candidate functional genes. The DNA region surrounding rs3780181 in intron 3 of VLDLR was used to design guide RNAs upstream (dark
gray bars) and downstream (white bar) and PCR elements (light gray bars) for the transcriptional reporter assays and to screen for deletion. (B and C) mRNA gene
expression in the unedited (WT and sort control) cell lines and edited (Enh1 and Enh2) cell lines for VLDLR and SMARCA2 was normalized to ACTB. (D) A proposed
molecular mechanism underlying the LDL-C and TC GWAS signal. The rs3780181 G allele differentially binds IRF2 and one other factor, increasing expression of VLDLR,
which leads to decreased LDL-C and TC.
Discussion
This study describes a molecular mechanism underlying the
LDL-C and TC GWAS signal at VLDLR (Fig. 2D). We showed that
evidence of association, LD and epigenomic annotation sup-
port rs3780181 as the best candidate functional variant for this
signal. When compared to the non-risk rs3780181 G allele, the
A allele showed significantly decreased enhancer activity in
hepatocytes, monocytes and preadipocytes consistent with the
association of rs3780181-A with lower VLDLR expression level in
human liver. We identified IRF2 as one of the nuclear proteins
that exhibited allelic differences in rs3780181 binding. Based on
eQTL, HiC interaction and gene expression after genome editing
to delete the rs3780181 enhancer, VLDLR showed the most con-
sistent evidence of a functional candidate gene. We propose that
differential binding of IRF2 and/or other transcription factors at
rs3780181 causes reduced expression of at least VLDLR, leading
to higher plasma LDL-C and TC levels.
VLDLR functions as a transporter for LDL family molecules by
binding and transporting apolipoprotein E and triglyceride-rich
lipoproteins into the cell (24,25). By regulating lipoprotein lipase,
VLDLR is involved in the catabolism of triglyceride-rich lipopro-
teins (24). VLDLR stimulates the ERK1/2 pathway and could have
a role in macrophage foam cell formation and atherosclero-
sis pathogenesis (26). VLDLR knockout mice have at least 69–
89% increased plasma lipids, consistent with the direction we
observed in humans by connecting the GWAS variants to gene
expression level (23,24). Given the known function of VLDLR and
the eQTL data connecting rs3780181 to VLDLR expression in
human liver tissues, the data from this study indicate that VLDLR
is the most compelling biological candidate gene in this region.
Deletion of the intronic enhancer also decreased expres-
sion level of SMARCA2, which encodes a chromatin remod-
eler. SMARCA2 has been shown to down-regulate CYP7A1
(27) and CYP7A1 deficiency in humans leads to increased
LDL-C (28). The rs3780181 GWAS signal has not yet been found
to be colocalized with expression level of SMARCA2, but we
cannot rule out that the eQTL studies are underpowered. Thus,
while VLDLR is a stronger biological candidate gene for this
GWAS signal, the enhancer containing rs3780181 may also
affect SMARCA2, which could also play a role in LDL-C and TC
levels.
Based on the EMSAs, several transcription factors showed
allelic differences in binding at rs3780181, including both puta-
tive activators and repressors. With THP-1 and HepG2 nuclear
extract, two protein complexes, including IRF2 or a family
member bound more strongly to the G allele, suggesting roles
as activators, and two unidentified protein complexes bound
more strongly to the A allele, suggesting roles as repressors. IRF
genes encode interferon regulatory factors, and levels of IRF1 are
positively correlated with oxidized-LDL in human THP-1
cell lines (29). Interleukin 6 is a known regulator of IRF1
and IRF2, and increased interleukin 6 led to increased
VLDLR expression in liver and adipose tissue, which led to
decreased blood TC and triglyceride levels in mice (30). The
in vivo effects of this and other transcriptional regulators that
alter VLDLR expression through this enhancer remain to be
identified.
One limitation of this study is that the most important cell
types for the molecular mechanism remain to be resolved. The
evidence supporting a role in liver includes the eQTL data, the
HepG2 and human liver chromatin marks at rs3780181 and the
allelic differences in transcriptional activity and transcription
factor binding observed with HepG2. However, VLDLR expression
level in liver is low. The eQTL associations could reflect other
cell types present in human liver, including blood cells and the
allelic effects may exist in other cell types not examined here.
Another limitation of this study is the cell type (HEK293T) used
for the in vivo genome-editing experiments. A cell type more
biologically relevant to cholesterol levels may implicate different
genes and/or provide biological evidence to link to metabolic
phenotypes. Further work is needed to understand the key cell
types relevant for the enhancer’s effect on VLDLR expression
level.
Together these data define an enhancer and suggest a molec-
ular mechanism by which a human GWAS signal affects VLDLR
and LDL-C and TC levels, thereby influencing cardiovascular risk.
Identifying and validating the connections between genetic vari-
ants and the effect on a broadly selected set of candidate genes




We considered any variants in high LD (r2 ≥ 0.7; 1000 Genomes
Project, phase 3) with rs3780181 in Europeans as a candidate
functional variant (31). We annotated the candidate functional
variants for overlap with regulatory data sets from the ENCODE,
the Roadmap Epigenomics Consortium and the RegulomeDB
(22,32,33). In these data sets, we considered histone epigenomic
marks H3K4me1 and H3K27ac as marks of enhancer activity
and DNase hypersensitivity, formaldehyde-assisted isolation of
regulatory elements-seq and assay for transposase-accessible
chromatin-seq as marks of accessible chromatin. We used chro-
matin immunoprecipitation data and TRANSFAC and ENCODE
motifs to identify candidate transcription factors at variant sites
(34,35).
Candidate gene annotation
We identified and visualized chromatin interaction between
candidate variant locations with Hi-C data sets using the Hi-
C unifying genomic interrogation (HUGIn) tool (12,36,37). We
evaluated the human primary tissues and assessed the HUGIn
significance P-values generated using Fit-Hi-C at chromosomal
segments overlapping transcription start sites to identify signif-
icant excess of chromatin interactions (38). We used the GTEx
Project database to compare candidate gene expression across
tissues (14). To identify eQTL with the candidate variants, we
evaluated liver eQTL data from the literature and searched the
GTEx v6 eQTL data using the lead GWAS variant(s), requiring an
association of P < 0.05 (20,21).
Transcriptional reporter and EMSAs
We tested allelic differences in transcriptional activity with
dual-luciferase reporter assays as previously described (18).
For the reporter assays, we designed polymerase chain reac-
tion (PCR) primers (5′-AGAGGCCTGCACTGGTAGAA and 5′-
CTCCACTAAAAGTTGAGGCTG) to amplify a 223 bp DNA element
surrounding rs3780181 from individuals homozygous for both
alleles. We cloned PCR products for each allele into the
firefly luciferase pGL4.23 reporter vector (Promega). We co-
transfected the constructs with phRL-TK renilla luciferase
reporter vector (Promega, Fitchburg, WI) into human THP-1
monocyte, SGBS preadipocyte and HepG2 hepatocyte cells. At
24–48 h post-transfection, we measured the luciferase activity
from cell extracts, normalized the firefly activity to renilla
activity and report activity relative to an empty pGL4.23 vector
control.
To conduct the EMSAs, we designed biotin-labeled and unla-
beled oligonucleotide probes (5′-TACTTTCA[A/G]TTTTCTAG-3′)
for both rs3780181 alleles (A/G), as previously described (18).
EMSAs were conducted using the LightShift Chemiluminescent
EMSA Kit (Thermo Fisher Scientific, Waltham, MA), following the
manufacturer’s protocol. Briefly, the oligonucleotides were incu-
bated with NE (4–5 μg, NE-PER kit, Thermo Fisher Scientific) from
THP-1 and HepG2 cell lines. To test the specificity of the protein
complexes to the specific allele, we added 45× excess compet-
itive unlabeled probes to the binding reactions. Protein–DNA
complexes were resolved by gel electrophoresis and transfer,
wash and detection steps were performed as described (18). To
conduct supershift assays, we added 4 μg of antibody to the
binding reactions for the following antibodies: IRF1 (sc-514544X,
Santa Cruz), IRF2 antibody (sc-374327X), IRF3 (sc-9082X), HMG1
(sc-26348X), RXRA (sc-553X) and NKX3.2 (sc-25066X).
Identification of protein complexes binding to
rs3780181
To identify factors in protein complexes binding rs3780181,
we perform a DNA-affinity capture assay using the micro
MACS FactorFinder Kit (Miltenyi Biotec, Bergisch Gladbach,
Germany), as described in (39). The binding reactions consisted
of 200 μg THP-1 NE, 50 pmol biotin probe for rs3780181 (as
in EMSAs), 1× protease inhibitor, 10 ng poly-dI:dC and 1×
binding buffer. Binding reactions were incubated for 25 min
and an additional 10 min with 75 μl streptavidin microbeads.
The binding reaction beads were washed with the MACS
columns following the kit protocol. The column eluate was
added to 80 μl 1× Nupage LDS sample buffer (Life Technologies,
Carlsbad, CA) with 1× NuPAGE reducing agent. The captured
protein for both alleles was subjected to electrophoresis on a
4–12% NuPAGE Bis-Tris Gel to a depth of 1 cm from the
bottom of the well. The proteins were identified by nano-liquid
chromatography followed by tandem mass spectrometry
analysis at the University of North Carolina (UNC) Proteomic
Core Facility (Supplementary Material, Table S1). We analyzed
the motifs of the identified proteins using TRANSFAC and
ENCODE matrices (34,35).
In vivo enhancer deletion
To conduct the CRISPR-cas9 assays, we designed pairs of single-
guide RNA (sgRNA) oligonucleotides in the genomic region
upstream and downstream of rs3780181 to create deletion of an
enhancer region in intron 3 of VLDLR (Supplementary Material,
Table S2). Two guide combinations (sgRNA1 + sgRNA3 and
sgRNA2 + sgRNA3) were used to create 663 bp (Enh2) and
475 bp (Enh1) deletions, respectively. The sgRNA guides
were cloned as previously described (40). Briefly, we cloned
the upstream sgRNAs into the pSpCas9(BB)-2A-GFP (PX458,
Addgene plasmid # 48138, a gift from Feng Zhang) and the
downstream sgRNA into a modified PX458 with a mCherry
reporter in place of the green fluorescent protein (GFC) (a
gift from Michael Stitzel, Jackson Laboratory for Genomic
Medicine) (18). We used native PX458 vectors without a sgRNA
to generate five non-edited clonal cell lines to control for
cell manipulation. We transfected the vectors into HEK293T
cells using Lipofectamine 2000 following the manufacturer’s
recommendations, sorted doubly fluorescent cells into 96-well
plates using a Becton Dickinson (Franklin Lakes, NJ) FACSAria II
and grew cell lines. We screened clonal cell lines for homozygous
deletions using PCR primers (5′-GGTCCTGGAAGCTAAGTCA and
5′-AAGCTGTGCCAACCTATGCT) to amplify an 899 bp region
surrounding all three sgRNAs; single-cell originating clonal
cell lines that yielded single PCR bands were considered
candidate homozygous deletions, and the PCR products were
Sanger-sequenced to confirm the deletion. We confirmed
that six clonal cell lines each for Enh1 and Enh2 have
homozygous deletions of the enhancer containing rs3780181
(Supplementary Material, Fig. S7).
mRNA gene expression assays
We extracted whole-cell RNA (RNeasy kit, Qiagen, Venlo,
Netherlands) from unedited HEK293T WT (3 replicates), mock-
edited control (control, 5 cell lines) and both sizes of homozygous
enhancer deletions (Enh1 and Enh2, 6 cell lines each) from
>80% confluent wells from 12-well plates. We prepared cDNA
libraries as previously described (18) and conducted real-time
PCR with TaqMan gene expression probes (Applied Biosystems,
Foster City, CA) for the following genes: VLDLR (Hs01045921 m1),
SMARCA2 (Hs01030846 m1), ACTB (Hs01060665 g1), KCNV2
(Hs00377936 m1) and VEGFA (Hs00900055 m1), following the
TaqMan assay protocol. Real-time PCR assays were conducted
in triplicate. To determine the significance of the deletions on
gene expression, the gene expression of Enh1 and Enh2 cell
lines were compared to the control cell lines using unpaired
t-tests.
Supplementary Material
Supplementary Material is available at HMG online.
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